SilcsBio, LLC Announces Issuance of US Patent with Utility in Drug Design Software

FOR IMMEDIATE RELEASE: July 12, 2018 Ken Malone SilcsBio, LLC 410.929.2305 Ken.Malone@silcsbio.com SilcsBio, LLC Announces Issuance of US Patent with Utility in Drug Design Software July 12, 2018 Baltimore, Maryland: SilcsBio, LLC (SilcsBio) announced today the issuance of a US patent covering key elements of SilcsBio’s drug design software. The SilcsBio software is broadly used[…]

SILCS-MC ranks top 10 on Free Energy Set 1 in the D3R Grand Challenge 2 on FXR

Grand Challenge 2 from D3R provided a farnesoid X receptor (FXR) target dataset to participants, which was used to test the performance of various computational approaches. SilcsBio’s SILCS-MC approach ranked 4th in Stage 1 and 6th in Stage 2 on the Free Energy Set 1 of this challenge. We used our unique SILCS approach to[…]

SilcsBio, LLC Announces Release of CGenFF 2.0.0

Baltimore, MD, 15 November 2016 Version 2.0.0 is the second release of CGenFF program, extending support to a larger variety of drug-like molecules to be used routinely in Computer-Aided Drug Design projects. Specifically, it improves treatment of halogen bonds, by introducing lone-pairs onto the halogen atoms of aromatic systems. Additionally, support is now extended to[…]

New Peer Reviewed Article Demonstrates SilcsBio, LLC’s Performance

New Peer Reviewed Article Demonstrates SilcsBio, LLC’s Performance Baltimore, Maryland, 4 November 2016 Recently published research has found that SilcsBio’s product, single-step free energy perturbation (SSFEP), demonstrated equal or more accurate results than standard free energy perturbation (FEP) but a thousand times faster. Additionally, SilcsBio’s site-identification by ligand competitive saturation (SILCS) product yielded relative free[…]

SilcsBio, LLC Receives Phase II NIH SBIR Funding

  FOR IMMEDIATE RELEASE: July 7, 2016 Ken Malone SilcsBio, LLC 410.929.2305 Ken.Malone@silcsbio.com   SilcsBio, LLC Receives Phase II NIH SBIR Funding   Baltimore, Maryland: SilcsBio, LLC announced today a $1.3 million funding award from the National Institute of Health to develop new computer aided drug design (CADD) software. CADD software enables pharmaceutical companies to[…]